2019 American Transplant Congress » Poster Session B: Kidney Immunosuppression: Induction Therapy
Date: Sunday, June 2, 2019
Time: 6:00pm-7:00pm
Location: Hall C & D
Session Type: Poster Session
Meeting: 2019 American Transplant Congress
- 6:00pm-7:00pm
Alemtuzumab Induction in Living Donor Renal Transplantation
O. Witkowsky, H. Winters, K. Washburn, G. Bumgardner, A. Rajab, A. El-Hinnawi, T. Pesavento
- 6:00pm-7:00pm
Alemtuzumab versus Anti-Thymocyte Globulin Induction in the Setting of Immediate Post-Renal Transplant Acute Tubular Necrosis in an Urban, Minority Patient Population
K. Tejani, E. Benedetti, A. Lichvar
- 6:00pm-7:00pm
Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients
A. Brueckner1, E. Yanqui1, C. Truong1, R. Baliga2, L. Bowman1
- 6:00pm-7:00pm
Basiliximab vs. Low-Dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients: Prospective Randomized Study in Southeastern Mexico
G. Martinez-Mier, P. I. Moreno-Ley, L. F. Budar-Fernandez, M. T. Mendez-Lopez, D. A. Barrera-Amoros, M. De la Paz-Roman, L. A. Jimenez-López, E. G. Aguilar-Sandoval, C. A. Allende-Castellanos
- 6:00pm-7:00pm
Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
S. J. Patel, S. Kuten, C. Pham, R. Knight, M. Hobeika, D. Nguyen, E. Graviss, S. Yi, T. Eagar, A. Gaber
- 6:00pm-7:00pm
Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression
J. A. Seaman1, S. G. Westphal2, F. Qiu3, D. Bremers4, D. Florescu5
- 6:00pm-7:00pm
Evaluation of Induction Immunosuppression in Elderly Kidney Transplant Recipients
C. Pham, S. Kuten, A. Rogers, R. Knight, D. T. Nguyen, E. Graviss, A. Gaber
- 6:00pm-7:00pm
Impact Of Rituximab And Maintenance Steroid In The Recurrence Of Focal Segmental Glomerulosclerosis
L. A. Mendez Castaner
- 6:00pm-7:00pm
Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk
C. Masset1, J. Boucquemont2, V. Garrigue3, M. Ladrière4, F. Buron5, E. Cassuto6, Y. Foucher2, J. Dantal1
- 6:00pm-7:00pm
Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Heart Transplant in the United States
S. M. Riad1, A. Tamas1, S. Jackson2, C. Martin1
- 6:00pm-7:00pm
Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Lung Transplant in the United States
S. Riad1, U. Goswami2, S. Jackson3, M. Hertz2
- 6:00pm-7:00pm
Induction with Thymoglobulin in DCD Kidneys. Dose Effect and Predictors of Outcome
A. Asderakis, T. Sabah, A. Jones, E. Ablorsu, L. Szabó, R. Chavez
- 6:00pm-7:00pm
Kidney Transplantation in Older Recipients with HLA-DR Mismatch: Impact of Induction Type on Outcomes
K. K. Sureshkumar1, N. L. Thai2, B. Chopra1
- 6:00pm-7:00pm
Living Donor Renal Transplantation without Any Induction Immunosuppression in Spousal Donors – Single Center Experience
R. Bhat, F. Aziz, I. N. Abubecker, S. Narayanan, B. Hafeeque
- 6:00pm-7:00pm
Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant
P. W. Baron1, J. Weissman2, F. Fazeli3, C. Zuppan4, R. Villicana3, P. Wai1, L. Beeson5, M. De Vera1
- 6:00pm-7:00pm
Outcomes Of Dosing Weight Selection On Rabbit Anti-thymocyte Globulin Induction Immunosuppression In High-risk, Obese Renal Transplant Recipients
A. C. Cordry1, K. Trobaugh1, L. Ramsey2, A. L. Castellanos3, H. Fattah3, T. Rendulic1
- 6:00pm-7:00pm
Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika
- 6:00pm-7:00pm
Outcomes of Reduced Thymoglobulin Induction Dosing in Elderly Kidney Transplant Recipients at a Steroid Sparing Center
E. C. Liu, J. H. Lee, R. Abramova
- 6:00pm-7:00pm
Panel Reactive Antibody Stratification as a Guide to Induction Selection in Deceased-Donor Kidney Transplantation: Impact of Clinical Practice on Outcomes
H. Ibrahim1, J. Gregg1, K. Alquadan1, U. Akanit2, K. L. Womer1, A. H. Santos1
- 6:00pm-7:00pm
Safety Outcomes in Elderly Patients Who Receive Alemtuzumab Induction for Kidney Transplant
S. Anders, A. Freeman, A. Mohammed, L. Hutchinson, U. Kaszubski, M. Janusek, J. Garces, H. Bohorquez
- 6:00pm-7:00pm
Safety and Efficacy of Alemtuzumab Compared to Rabbit Anti-Thymocyte Globulin as Induction for Secondary Transplant after a Primary Transplant with Alemtuzumab Induction
J. L. Fose1, M. R. Jorgenson1, G. E. Leverson2, R. R. Redfield2
- 6:00pm-7:00pm
Thymoglobulin Versus Alemtuzumab Induction in High Immunologic Risk Kidney Transplants
J. Lockridge1, J. Pryor1, D. Norman1, A. Olyaei2
- 6:00pm-7:00pm
Type of Induction Does Not Impact Patient or Kidney Allograft Survival in Simultaneous Liver and Kidney Transplant Recipients in the United States
S. Riad1, N. Lim2, S. Jackson3, J. Lake2
« View all sessions from the 2019 American Transplant Congress